Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
07 March 2018 Photo Xolisa Mnukwa
UJ to benchmark Kovsie CUADS operational services
UJ Disability unit delegates Alban Burke and Leila Abdul Gafoor join UFS CUADS Assistant director, Martie Miranda and Dean of Student Affairs, Pura Mgolombane for a discussion on the operative aspects of the UFS Center for Universal Access and Disability Support.

The University of Johannesburg (UJ) Psychological Services and Career Development Department is looking to enhance the quality of services provided by its disability unit. Team leader of the Psychological Services division at (PsCAD): Leila Abdul Gafoor said University of the Free State (UFS) was on its list of targets when it boiled down to possibly benchmarking and sharing the Center for universal access and disability support (CUADS) service structures and operational procedures that could aid a more pleasant and complete university experience for students with disabilities at UJ.

Director of PysCad at UJ, Alban Burke, considered one of the strengths of his department to be its ability to serve as a hot-stop for their students with academic opportunities that could assist them financially, psychologically, intellectually and perceptually. He did, however, point out that one of their main challenges lies in their difficulty sourcing capital and resources that are exclusive to the disability unit within his department which is very expensive to operate and sustain. 

Dean of Student Affairs, Pura Mgolombane, started his response to PysCad delegates with the question: “Which strategies should be operationalised in order to cater for the core needs of students?” He said the strategy should inform the operational structure that a university employs. Thus, the strategy should centre universal access as the Integrated Transformation Plan (ITP) intended it, and in that way the structure would need to support the notion of universal access; and therefore address student needs. The UFS is currently undergoing a phase of integrated transformation which Mgolombane explained which among other things, demanded avid preparations towards ensuring that universal access was prioritised. 

Martie Miranda, Assistant Director for CUADS, clarifies that CUADS considered repositioning its office beneath academics due to a majority of their occupational services comprising of academic support for students with disabilities. However, due to Student Affairs’ newly developed “humanising strategic model” the centre remained put as they are being afforded efficient opportunity to change mindsets, and create an institutional culture which endorses the humanising of students with disabilities as well.

Mgolombane said in order for an institution to deliver sufficient universal access, students’ needs and experiences had to be considered and prioritised from conception. The planning and future implementation should not serve as an afterthought when allocating financial, human, physical and other resources to the various university environments. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept